Biologics, with their precision targeting, expand treatment options for a multitude of diseases - from cancer to autoimmune disorders. In 2023 alone, 10 antibody therapeutics received their first ...

In this interview, industry experts Mathieu Bennet and Dustin Whitson explore how automation and single-cell technologies are transforming high-throughput B-cell cloning for antibody discovery. Can ...

This presentation looks at the dynamic landscape of therapeutic antibody development, focusing on next-generation immuno-oncology therapeutics that target checkpoint inhibitors and incorporate the ...

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced it has been named a leader in the ...

In this Teach Me in 10, Dr. Kelly Flook, Senior Product Manager at Thermo Fisher Scientific, explains how affinity ...

To address the demand for rapid, highly specific therapeutic candidates, Creative Biolabs has optimized its comprehensive ...

Bispecific antibodies (bispecifics) can simultaneously target two distinct antigens or epitopes, offering novel therapeutic strategies such as enhancing immune cell targeting of cancer cells or ...

The increase in the utilization of monoclonal antibodies as therapeutics over the past two decades has been remarkable, with over 80 mAbs approved for use. The quick pace of clinical studies and ...

The oPool + display platform combines technologies to make and test large numbers of antibodies at once. Antibodies are the critical targeting agents of the immune system and the crux of immune ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Large molecule, protein-based biopharmaceuticals can have significant advantages over conventional small molecule pharmaceuticals including greater specificity, lower toxicity, and higher efficacy.

The history of antibody engineering and production in drug discovery can be traced back to the 1970s and 1980s [1] when scientists first began to explore the potential of using antibodies as ...